iBionext Completes First Closing of 46 M€ for Its Fund iBionext Growth Fund

The new venture capital fund is accelerating its investments in disruptive healthcare technologies

PARIS--()--iBionext Growth Fund, a new venture capital fund launched in early 2016, which specializes in the creation and development of innovative healthcare start-ups, today announced a first closing of 46 M€.

The fund, whose target is to reach approximately 100 M€, has drawn interest from leading international investors, insurance companies and family offices, alongside the Biotech & Healthcare Acceleration Fund (FABS) operated by Bpifrance in the context of the Investments for the Future Program (PIA) managed by General Commissariat for Investment (CGI).

Alexia Perouse, CEO & Managing Partner of iBionext commented: "We are delighted to have generated such momentum around our unique initiative and we thank our investors for the confidence they have placed in us. iBionext operates with a very entrepreneurial approach designed to meet the challenges that innovative healthcare companies can face, from creation to growth, with the goal of creating leaders in their field.”

Created as an extension of iBionext network established in 2012, iBionext Growth Fund is positioned as the missing link in the financing chain of innovative healthcare companies with a three-step operating model: "Spot, Boost & Grow".

iBionext enjoys a privileged access to breakthrough technologies in healthcare, notably through its network of scientists and experts from the most prestigious R&D centers worldwide. The operating model implemented by the management team selects high potential disruptive technologies with highly unmet medical needs in the fields of biotech, medtech and connected medical devices.

Located in a single site in Paris named "Passage of innovation", the companies supported by the iBionext network create an exceptional ecosystem conducive to knowledge and expertise sharing.

Seven companies have been created since 2012, including Pixium Vision (Euronext: PIX) GenSight Biologics (Euronext: SIGHT), and Gecko Biomedical, which are widely recognized for their disruptive innovations in healthcare.

Bernard Gilly, President and Founder of iBionext said: "I am delighted that our investors have shown interest in the iBionext approach, which renews and completes the financial model of traditional venture capital. While iBionext Growth Fund initiates its first investments in new projects, we will continue the fundraising process to reach the target size of 100M€”

About iBionext: http://ibionext.com/

Contacts

iBionext
+331 76 21 47 50
www.ibionext.com, @iBionext
contact@ibionext.com
or
Press contact
Annie-Florence Loyer, 06.88.20.35.59
afloyer@newcap.fr

Release Summary

IBIONEXT COMPLETES FIRST CLOSING OF 46 M€ FOR ITS FUND IBIONEXT GROWTH FUND. The new venture capital fund is accelerating its investments in disruptive healthcare technologies.

Social Media Profiles

Contacts

iBionext
+331 76 21 47 50
www.ibionext.com, @iBionext
contact@ibionext.com
or
Press contact
Annie-Florence Loyer, 06.88.20.35.59
afloyer@newcap.fr